Accuray (NASDAQ:ARAY – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

NHS England has been branded 'scandalous' after it emerged that five life saving cancer machines are not being replaced ...

The CyberKnife system, which remains the only truly robotic radiotherapy system, dedicated to SBRT and stereotactic radiosurgery treatments, grew revenue well above 50% year over year, so great ...

Q2 2025 Earnings Call Transcript February 5, 2025 Accuray Incorporated beats earnings expectations. Reported EPS is $0.02, ...

CyberKnife radiosurgery is a 15-minute outpatient procedure that requires no anesthesia or hospital admission, offering a non ...

Accuray Inc (ARAY) reports an 8% revenue increase, driven by robust product sales and significant growth in China and Japan.

Q2 2025 Management View Suzanne Winter, CEO, highlighted an 8% year-over-year revenue growth for Q2, supported by robust product revenue growth of 19%, and a strong adjusted EBITDA performance of ...

Reports Q2 revenue $116.2M, consensus $110.36M. “Our strong Q2 performance reflects outstanding execution of our strategies of advancing ...

To deal with deadly diseases like cancer in the country, the government is trying its best to cure people by bringing different types of world-class treatments. In this series, the Gujarat Cancer and ...

President William Ruto has commissioned a cyberknife at the Kenyatta University Teaching, Referral and Research Hospital (KUTRRH) which will be used to provide better health services for non ...